Mass treatment to eliminate filariasis in Papua New Guinea

被引:109
|
作者
Bockarie, MJ
Tisch, DJ
Kastens, W
Alexander, NDE
Dimber, Z
Bockarie, F
Ibam, E
Alpers, MP
Kazura, JW
机构
[1] Case Western Reserve Univ, Sch Med, Div Geog Med, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Ctr Int Hlth, Cleveland, OH 44106 USA
[3] Univ Hosp Cleveland, Cleveland, OH 44106 USA
[4] Papua New Guinea Inst Med Res, Goroka, Papua N Guinea
[5] London Sch Hyg & Trop Med, London WC1, England
[6] Curtin Univ, Ctr Int Hlth, Perth, WA, Australia
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2002年 / 347卷 / 23期
关键词
D O I
10.1056/NEJMoa021309
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The global initiative to eradicate bancroftian filariasis currently relies on mass treatment with four to six annual doses of antifilarial drugs. The goal is to reduce the reservoir of microfilariae in the blood to a level that is insufficient to maintain transmission by the mosquito vector. Methods: In nearly 2500 residents of Papua New Guinea, we prospectively assessed the effects of four annual treatments with a single dose of diethylcarbamazine plus ivermectin or diethylcarbamazine alone on the incidence of microfilariae-positive infections, the severity of lymphatic disease, and the rate of transmission of Wuchereria bancrofti by mosquitoes. Random assignment to treatment regimens was carried out according to the village of residence, and villages were categorized as having moderate or high rates of transmission. Results: The four annual treatments with either drug regimen were taken by 77 to 86 percent of the members of the population who were at least five years old; treatments were well tolerated. The proportion with microfilariae-positive infections decreased by 86 to 98 percent, with a greater reduction in areas with a moderate rate of transmission than in those with a high rate. The respective aggregate frequencies of hydrocele and leg lymphedema were 15 percent and 5 percent before the trial began, and 5 percent (P<0.001) and 4 percent (P=0.04) after five years. Hydrocele and leg lymphedema were eliminated in 87 percent and 69 percent, respectively, of those who had these conditions at the outset. The rate of transmission by mosquitoes decreased substantially, and new microfilariae-positive infections in children were almost completely prevented over the five-year study period. Conclusions: Annual mass treatment with drugs such as diethylcarbamazine can virtually eliminate the reservoir of microfilariae and greatly reduce the frequency of clinical lymphatic abnormalities due to bancroftian filariasis. Eradication may be possible in areas with moderate rates of transmission, but longer periods of treatment or additional control measures may be necessary in areas with high rates of transmission.
引用
收藏
页码:1841 / 1848
页数:8
相关论文
共 50 条
  • [1] Reduction in Acute Filariasis Morbidity during a Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea
    Tisch, Daniel J.
    Alexander, Neal D. E.
    Kiniboro, Benson
    Dagoro, Henry
    Siba, Peter M.
    Bockarie, Moses J.
    Alpers, Michael P.
    Kazura, James W.
    PLOS NEGLECTED TROPICAL DISEASES, 2011, 5 (07):
  • [2] Mass treatment with ivermectin for filariasis control in Papua New Guinea: impact on mosquito survival
    Bockarie, MJ
    Hii, JLK
    Alexander, NDE
    Bockarie, F
    Dagoro, H
    Kazura, JW
    Alpers, MP
    MEDICAL AND VETERINARY ENTOMOLOGY, 1999, 13 (02) : 120 - 123
  • [3] Mass treatment of filariasis in New Guinea
    Rajendran, R
    Sunish, IP
    Mani, TR
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (12): : 1180 - 1180
  • [4] A TRIAL OF A NOVEL TRIPLE DRUG TREATMENT FOR LYMPHATIC FILARIASIS IN PAPUA NEW GUINEA
    King, Christopher
    Suamani, James
    Sanuku, Nelly
    Cheng, Yao-Chieh
    Satofan, Samson
    Mancuso, Brooke
    Robinson, Leanne
    Siba, Peter
    Weil, Gary
    Kazura, James
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2018, 99 (04): : 656 - 656
  • [5] EPIDEMIOLOGY OF LYMPHATIC FILARIASIS DURING MASS DRUG ADMINISTRATION IN DREIKIKIR, PAPUA NEW GUINEA
    Tisch, Daniel J.
    Mancuso, Brooke
    Sanuku, Nelly
    Lus, Philip
    Cramer, Estee
    Pomat, Willie
    King, Christopher L.
    Zimmerman, Peter A.
    Kazura, James W.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2019, 101 : 561 - 562
  • [6] Lymphatic filariasis in Papua New Guinea: prospects for elimination
    Bockarie, MJ
    Kazura, JW
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2003, 192 (01) : 9 - 14
  • [7] Migration and dispersal of lymphatic filariasis in Papua New Guinea
    Alexander, NDE
    Bockarie, MJ
    Dimber, ZB
    Griffin, L
    Kazura, JW
    Alpers, MP
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2001, 95 (03) : 277 - 279
  • [8] Lymphatic filariasis in Papua New Guinea: prospects for elimination
    Moses J. Bockarie
    James W. Kazura
    Medical Microbiology and Immunology, 2003, 192 : 9 - 14
  • [9] TRANSMISSION INTENSITY AND BIOMARKERS OF WUCHERERIA BANCROFTI INFECTION 10 YEARS AFTER CESSATION OF MASS DRUG ADMINISTRATION TO ELIMINATE LYMPHATIC FILARIASIS IN PAPUA NEW GUINEA
    Tisch, Daniel J.
    Kastens, Will
    Moses, Bockarie J.
    Baisor, Moses
    Susapa, Melinda
    Sepe, Daphne
    Baia, Kay
    Baia, Manasseh
    Reeder, John
    Michael, Edwin
    Siba, Peter
    Kazura, James W.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2009, 81 (05): : 294 - 294
  • [10] COMPREHENSIVE MONITORING OF THE IMPACT OF A PILOT MASS DRUG ADMINISTRATION PROJECT FOR FILARIASIS IN PAPUA NEW GUINEA
    Weil, Gary J.
    Kastens, Will
    Susapu, Melinda
    Laney, Sandra
    Williams, Steven A.
    King, Chrisopher L.
    Kazura, James W.
    Bockarie, Moses J.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2008, 79 (06): : 326 - 326